Why the study?
All CMS State Innovation Models (SIM) states focus on improving diabetes care, but the initiative's effect on 30-day readmissions among adults with diabetes remained unclear.
Does the CMS State Innovation Models (SIM) Initiative reduce 30-day hospital readmissions in hospitalized adults with diabetes?
Does the CMS State Innovation Models (SIM) Initiative reduce 30-day hospital readmissions in hospitalized adults with diabetes?
The CMS State Innovation Models Initiative did not reduce 30-day hospital readmissions among adults with diabetes during its first two years of implementation.
SIM's effect on diabetes readmissions remains uncertain; leaves open whether state reforms meaningfully reduce hospitalizations.
BACKGROUND: The Centers for Medicare & Medicaid Services (CMS) State Innovation Models (SIM) Initiative funds states to accelerate delivery system and payment reforms. All SIM states focus on improving diabetes care, but SIM's effect on 30-day readmissions among adults with diabetes remains unclear. METHODS: A quasi-experimental research design estimated the impact of SIM on 30-day hospital readmissions among adults with diabetes in 3 round 1 SIM states (N=671,996) and 3 comparison states (N=2,719,603) from 2010 to 2015. Difference-in-differences multivariable logistic regression models that incorporated 4-group propensity score weighting were estimated. Heterogeneity of SIM effects by grantee state and for CMS populations were assessed. RESULTS: In adjusted difference-in-difference analyses, SIM was associated with an increase in odds of 30-day hospital readmission among patients in SIM states in the post-SIM versus pre-SIM period relative to the ratio in odds of readmission among patients in the comparison states post-SIM versus pre-SIM (ratio of adjusted odds ratio=1.057, P=0.01). Restricting the analyses to CMS populations (Medicare and Medicaid beneficiaries), resulted in consistent findings (ratio of adjusted odds ratio=1.057, P=0.034). SIM did not have different effects on 30-day readmissions by state. CONCLUSIONS: We found no evidence that SIM reduced 30-day readmission rates among adults with diabetes during the first 2 years of round 1 implementation, even among CMS beneficiaries. It may be difficult to reduce readmissions statewide without greater investment in health information exchange and more intensive use of payment models that promote interorganizational coordination.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: